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Abstract
Angiotensin converting enzyme inhibitors may improve exercise capacity and muscle function in older people but are often
thought to increase falls risk. We investigated the effect of perindopril on postural stability in older people with a history of falls.
Design: double-blind, parallel group, placebo-controlled randomised trial.
Methods: we recruited people aged >65 years with at least one fall in the previous year. Participants received 4 mg perindo-
pril or placebo daily for 15 weeks. The primary outcome was the between-group difference in force-plate measured antero-
posterior (AP) sway at 15 weeks. Secondary outcomes included other measures of postural sway, limits of stability during
maximal forward, right and left leaning, blood pressure, muscle strength, 6-min walk distance and falls. The primary out-
come was assessed using two-way ANOVA, adjusted for baseline factors.
Results: we randomised 80 participants. Mean age was 78.0 (SD 7.4) years; 60 (75%) were female. About 77/80 (96%)
completed the trial. At 15 weeks there were no signiﬁcant between-group differences in AP sway with eyes open (mean dif-
ference 0 mm, 95% CI −8 to 7 mm, P = 0.91) or eyes closed (mean difference 2 mm, 95% CI −7 to 12 mm, P = 0.59); no
differences in other measures of postural stability, muscle strength or function. About 16/40 (42%) of patients in each
group had orthostatic hypotension at follow-up. The median number (IQR) of falls was 1 (0,4) in the perindopril versus
1 (0,2) in the placebo group (P = 0.24).
Conclusions: perindopril did not improve postural sway in older people at risk of falls.
Clinical Trials Registration: ISRCTN58995463
Keywords: Falls, clinical trial, angiotensin converting enzyme inhibitor, postural sway, older people
Introduction
One in three community-dwelling individuals over 65 fall at
least once per year with resultant injury, disability, loss of con-
ﬁdence, dependence on others and poor quality of life.
Postural instability, a major risk for falls, increases with age [1].
Exercise is the single most effective intervention for falls
prevention, and both lower limb strength and balance train-
ing and tai chi programmes can reduce falls risk—primarily
through a reduction in postural instability [2, 3].
Although antihypertensive medication are commonly thought
to cause falls, angiotensin converting enzyme inhibitors (ACEi)
might in fact have a number of effects that could lead to a reduc-
tion in falls risk. ACEi can improve 6-min walking distance in
older people to a similar extent as 6 months of an exercise pro-
gramme that reduced falls and is associated with a slower decline
in muscle strength and walking speed with ageing [4, 5].
Other effects include beneﬁcial effects on nerve function
[6, 7], central postural control [8] and orthostatic hypotension
(OH) related to baroreceptor sensitivity [9]. Population based
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studies in older people have variously reported an increased
[10–12], unchanged [13, 14] or a reduced [15] risk of falls,
especially injurious ones, with cardiovascular medications like
ACEi.
Randomised controlled trials are required to resolve this
uncertainty; we therefore tested the effect of the long-acting
ACEi perindopril on postural instability as an intermediate
phenotype that reﬂects falls risk in older people.
Methods
We performed a parallel group, double-blind randomised
placebo-controlled trial. The study followed the principles
of the Declaration of Helsinki was approved by the
Scotland—A Research Ethics committee (13/SS/0086) and
the Medicines and Healthcare Regulatory Authority
(EuDRACT number 2013-001677-24). The trial was regis-
tered with www.isrctn.com (ISRCTN58995463). The work
was supported by funding from the Scottish Chief Scientist
Ofﬁce (grant number CZH/4/856). The funders had no
role in the design, execution, analysis and interpretation of
data, or writing of the study report.
We recruited community-dwelling participants from the
Tayside area of Scotland, aged ≥65 years with at least one self-
reported fall in the previous 12 months. To ensure that all par-
ticipants had had the opportunity to engage with currently
provided strategies for falls management, we recruited only
people who had sought medical attention for a fall within the
last 18 months. Exclusion criteria were: already taking ACEi
or Angiotensin Receptor Blocker (ARB); contraindication to
ACEi (previous intolerance; signiﬁcant aortic outﬂow obstruc-
tion with peak gradient >30mmHg; serum potassium >5.0
mmol/l; eGFR < 30ml/min/1.73 m2 by MDRD4 equa-
tion [16]; serum creatinine >170 umol/l); stopped ACEi or
ARB following specialist falls assessment in the previous 6
months; a clinical diagnosis of heart failure; asymptomatic left
ventricular systolic dysfunction; Systolic blood pressure (BP)
>160mmHg or <100mmHg at screening or on 24 h BP
monitor within the last year; wheelchair bound; inability to
stand or walk without assistance; Parkinson’s disease; taking
non-steroidal anti-inﬂammatory drugs (aspirin was permitted);
participation in a previous clinical trial of investigational medi-
cinal products within 30 days; lactose intolerance; cognitive
impairment precluding informed consent.
We identiﬁed participants from a variety of sources: (i)
Letters of invitation through the East node of the Scottish
Primary Care Research Network (SPCRN); (ii) Local Day
Hospitals, outpatient clinics, falls services, and elderly ser-
vices; (iii) Advertising in community settings; (iv) Volunteer
databases including the Scottish Health Research Register.
We prescreened potential participants for eligibility via tele-
phone (see Supplementary data, Appendix 1, available at Age
and Ageing online).
We randomised participants using a web-based ran-
domisation system run independently from the trial team
by Tayside Clinical Trials Unit (TCTU) to ensure allocation
concealment. Eligible participants received either Perindopril
or placebo identically over-encapsulated, for 15 weeks in a
1:1 ratio. We employed a minimisation algorithm using three
factors: baseline systolic BP (> or <140mmHg), thiazide diur-
etic use and source of recruitment (Primary care and volun-
teers; secondary care falls services; and other secondary care).
After 2 weeks, perindopril was up-titrated from 2mg to 4mg
with mock up-titration of placebo. All usual medication was
continued.
Outcomes
We measured outcomes at baseline and 15 weeks during a
hospital-based study visit. The primary outcome was the
between-group difference in static Anteroposterior (AP) sway
from baseline to 15 weeks, adjusted for baseline values.
Postural stability
Postural stability was measured using a force-plate (AMTI
model BP400600, Advanced Mechanical Technologies Inc.
Watertown, MA, USA). For static postural stability, partici-
pants stood on the force-plate with feet slightly apart for
40 s. The largest value from three runs was used for ana-
lyses. Each set of runs was performed with eyes open, then
with eyes closed. A scatter plot of the AP and Medio-
Lateral (ML) displacement of centre of pressure (COP) was
used to calculate AP and ML sway, total sway area (TSA) [17]
and average sway velocity (SV). For dynamic postural stability,
the maximum COP displacement during three 5 second trials
of maximal forward, right and left leaning was measured with
eyes open to measure limits of stability (LOS) [18].
Physical function measures
We measured quadriceps strength, non-volitional muscle
strength using magnetic femoral nerve stimulation and 6-min
walk (6MW) distance were recorded (see Supplementary data,
Appendix 1, available at Age and Ageing online).
Falls
Participants prospectively recorded falls using the validated
monthly fall diaries method [19]. Diaries were administered
at the baseline visit and returned at the 15 week visit.
Participants were instructed on what was considered a fall
and asked to complete the diary daily. They were reminded
about the diaries at each visit/telephone call.
Other measures
We recorded baseline information on age, sex, height,
weight, body mass index (BMI), bioimpedance measures of
muscle and fat mass (BIA 101, Akern, Pontasseive, Italy),
concomitant medications, co-morbidities, smoking, alcohol
consumption, type of accommodation, Scottish Index of
Multiple Deprivation (SIMD) and walking aid use.
Blood pressure was measured at baseline and 15 weeks
using a standard digital monitor (Omron 705IT; Milton
D. Sumukadas et al.
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Keynes, UK) in the supine position and then immediately on
standing, repeated at 2 and 3 min, to identify OH. OH was
deﬁned as a reduction of BP systolic >20mmHg or diastolic
>10mmHg within 3 min of standing as per the consensus
statement from a group of leading scientiﬁc societies [20].
Statistical analysis
Sample size calculation
We anticipated a reduction in mean AP sway of 5.6 mm
(SD 7.1) from a baseline of 24.5 mm between perindopril
and placebo group as seen with Tai Chi [17], a recom-
mended intervention for falls prevention. To detect this
change with 90% power at alpha = 0.05, we required 34
participants per group. Allowing for a dropout of 15%, we
aimed to recruit 80 participants (40 per group).
We recorded data using the OpenClinica database sys-
tem (OpenClinica, Waltham, MA 02451, USA), which was
locked prior to ﬁnal analysis. Analyses were conducted by a
statistician in Tayside CTU using the SAS statistical package
(SAS Institute Inc., North Carolina, USA, version 9.3). For
all outcomes save falls, analyses were performed comparing
difference in outcomes at 15 weeks using ANOVA,
adjusted for baseline values of the variable under test. The
fully adjusted analysis entered all independently signiﬁcant
baseline covariates into a multivariate model; only those
covariates retained in a backwards elimination analysis were
included in the ﬁnal adjusted model. Between-group
changes in outcomes were analysed on an intention to treat
basis. A sensitivity analysis using multiple imputation to
account for missing data was also performed, using the
combined results from 100 rounds of imputation. To take
into account the highly skewed distribution of number of
falls we tested a series of models including ANOVA, other
distributions (quasi-poisson) and ordinal data categorising
participants as having 0, 1–2, 3–5, 6–10 and >10 falls.
Results
In total 4,289 potential participants were invited to partici-
pate in the study. About 3,793 (88%) declined or did not
reply, 408 (9.5%) were found to be ineligible at pre-screening
(most frequent reasons were already taking ACEi, taking
NSAIDS, not had a fall in previous 18 months or not sought
medical attention for falls). Of the case, 88 attended a screen-
ing visit, and 80 participants progressed to randomisation
between September 2013 and September 2015. About 77/80
(96%) completed the study. The CONSORT participant
ﬂow diagram is given in Figure 1. The two groups were well
matched at baseline (Table 1). Study medication was stopped
in 7 participants taking perindopril (4 for cough, 1 increased
potassium, 1 participant felt was causing muscle weakness, 1
commenced on ACEi for hypertension) and 2 taking placebo
(1 for dizziness, 1 participant choice). Two participants in
the perindopril group remained on the 2 mg dose due to
complaints of dizziness (both had OH at screening but
only 1 at follow-up).
Primary outcome
There was no signiﬁcant difference in change in AP sway
between groups with eyes open (mean difference 0 mm,
95% CI −8 to 7 mm, P = 0.91) or eyes closed (mean differ-
ence 2 mm, 95% CI −7 to 12 mm, P = 0.59). Details of the
primary outcome analyses are given in Table 2. After adjust-
ing for all signiﬁcant univariate factors (baseline AP sway,
height and walking aids) difference in AP sway with eyes
closed was 6 mm (95% CI −2 to 13 mm) and with eyes
open was 0 mm (95% CI −7 to 7 mm).
The number of dropouts was low (n = 3). There was no
signiﬁcant between-group difference in change in AP sway
when multiple imputation was used to account for missing
data; AP sway mean difference was 3 mm (95% CI −6 to
12 mm; P = 0.5) with eyes closed 0 mm (95% CI −8 to
7 mm; P = 0.92) with eyes open.
Secondary outcomes
Postural stability
There were no signiﬁcant differences between groups in
change in ML sway, SV or TSA or in Dynamic stability
measures of LOS whilst reaching forward, left or right (see
Supplementary data, Appendix 2, available at Age and Ageing
online).
Physical function measures
There were no signiﬁcant differences between groups in
change in voluntary or involuntary muscle strength.
Difference in 6 MW distance between groups was −9 m
(95% CI −29 to 12; P = 0.41) (Table 2).
Blood pressure
A treatment effect was seen in both systolic (−11 mmHg
95% CI −18 to −4; P = 0.003) and diastolic (−5 mmHg
95% CI −9 to −1; P = 0.02) BP at 15 weeks. There was
no difference between groups in postural drop in BP
(−1 mmHg 95% CI −6 to 4, P = 0.78) or the number of
people fulﬁlling the criteria of OH (16 in both groups;
P = 0.90) (Table 2).
No participant died in the study period. Hospital admis-
sion occurred in 1 participants in the perindopril group
(2 admissions for breast abscess and subcutaneous abscess)
and 3 in the placebo group (1 for stroke and ankle facture;
1 dizziness and fall; 1 biliary sepsis). Adverse events were com-
mon (perindopril n = 84 versus placebo n = 82). Most adverse
events (70%) were of mild severity (see Supplementary data,
Appendix 3, available at Age and Ageing online).
The number of falls was greater in the perindopril group
(156 versus 95), but the data were heavily skewed by a small
number of participants who fell frequently. More frequent
falls in the perindopril group during the trial period
reﬂected a higher rate of falls in this group prior to trial
enrolment (592 versus 536). More participants in the peri-
ndopril group had no falls during the trial (17 versus 13).
The effect of perindopril on postural instability in older people with a history of falls
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The median number (IQR) of falls was 1 (0,4) in the peri-
ndopril group versus 1 (0,2) in the placebo group. The dif-
ference between groups was not statistically signiﬁcant
(difference in mean number of falls per person by ordinal
regression 0.4 [95% CI −9 to 1.6]; P = 0.58) (see
Supplementary data, Appendix 4, available at Age and Ageing
online).
Discussion
We found no statistically signiﬁcant effect of 15 weeks of
perindopril on postural stability in older people with falls,
albeit with wide conﬁdence intervals. This suggests that
perindopril may not be an effective treatment to improve
postural stability in those who had received all currently
available standard therapy for falls. An important caveat is
that the minimal clinically important difference in stability
measures for falls risk reduction is not known and there is
variability in the techniques used to measure postural stabil-
ity [21]; our results cannot exclude a possibly clinically
important effect.
More positively, perindopril did not appear to worsen
OH. ACEi are often discontinued in people with falls due
to the widespread belief that antihypertensive medication
exacerbates OH and increases falls. The evidence linking
long-acting ACEi with OH is weak however. People with
Community
Volunteer databases, posters, 
community centres, press 
sheltered housing, (n = 175)
Primary Care
GP pracces - pre-screened
and sent leers (n = 3791)
Medicine for the elderly (MFE) & falls services
Approached whilst aending clinical services: 
(n = 323)
MFE (n = 221) & Falls (n = 102)
Ineligible (n = 234)
Declined (n = 58)
Ineligible (n = 118)
Declined (n = 23
Respondents pre-screened
by telephone (n = 100)
Failed screening (n = 8)
4 Systolic blood pressure >160 mmHg
1 Systolic blood pressure <100 mmHg
3 serum potassium >5.00mmol/L
Aended screening (n = 88)
23 Primary care
34 Community
31 MFE & falls related services
Randomised (n = 80)
21 Primary care
32 Community
3 MFE
24 falls related services
15 week follow up
Placebo group 
(n = 40)
Perindopril 
group (n = 40)
2 parcipants lost to follow up 
(stroke, palpitaons)
1 parcipant lost to follow 
up (chest infecon)
Completed 
study (n = 38)
Completed 
study (n = 39)
Ineligible (n = 56)
Declined (n = 21)
No response or 
declined (n = 3691)
Figure 1. CONSORT Flow chart for trial participation.
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controlled hypertension have a lower prevalence of OH
than those with uncontrolled hypertension and OH is asso-
ciated with a 2.5 times higher risk of falls in those with
uncontrolled compared to those with controlled hyperten-
sion [22]. Population based studies in older people have
variously reported an increased [10–12], unchanged [13, 14]
or a reduced [15] risk of falls, especially injurious ones, with
cardiovascular medications like ACEi. The results from the
current trial suggest that ACEi may not increase falls risk in
older people who fall. This ﬁnding should be interpreted
with caution as our study was not powered to detect falls as
an outcome, but was included as a safety measure and con-
ﬁdence intervals are wide. Moreover there was an imbal-
ance in the number of falls between groups at baseline.
Trial results in this area are scanty; a recent medication
withdrawal trial [23] showed no beneﬁt from withdrawal of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Baseline characteristics
Perindopril (n = 40) Placebo (n = 40)
Mean age (years) (SD) 78.1 (7.3) 78.0 (7.6)
Male sex (%) 10 (25) 10 (25)
Mean BMI (kg/m2) (SD) 29.0 (4.3) 28.5 (5.2)
Height-adjusted muscle mass kg/m (SD) 13.9 (2.9) 13.7 (3.0)
Height-adjusted fat mass kg/m (SD) 18.9 (4.9) 18.2 (5.8)
Mean eGFR 73.4 (21.5) 76.7 (21.7)
Mean SBP mmHg (SD) 147 (13) 143 (14)
Mean DBP mmHg (SD) 82 (11) 76 (11)
OH present 11 (28) 13 (33)
Walking aid
None (%) 20 (50) 19 (47)
Walking stick (%) 16 (40) 14 (35)
Other (%) 4 (10) 7 (18)
Co-morbidities
Hypertension (%) 16 (40) 16 (40)
Cardiovascular disease (%) 8 (20) 6 (15)
Peripheral neuropathy (%) 2 (5) 7 (18)
Vertigo (%) 3 (7) 4 (10)
Registered blind (%) 1 (2) 0
Concomitant medications
Total number of medications median (IQR) 7 (4,9) 6 (4,8)
Number cardiovascular medications median (IQR) 1 (0,2) 1 (0,2)
Any Cardiovascular medication (%) 26 (65) 24 (60)
Sedatives and antipsychotics (%) 2 (5) 2 (5)
Opioid based analgesia (%) 10 (25) 5 (13)
eGFR, estimated Glomerular Filtration Rate; SBP/DBP, systolic/diastolic blood pressure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Outcome measures
Perindopril Placebo Treatment effecta (95% CI) P
Primary outcome
AP sway range (mm) (eyes closed) Baseline N = 36 63 (33) N = 39 64 (35) 2 (−7 to 12) 0.59
Follow-up N = 34 59 (31) N = 37 57 (31)
AP sway range (mm) (eyes open) Baseline N = 40 53 (27) N = 40 53 (30) 0 (−8 to 7) 0.91
Follow-up N = 39 45 (19) N = 38 45 (28)
Secondary outcomes
Maximal voluntary quadriceps contraction (kg) Baseline N = 39 18.6 (9.0) N = 39 19.2 (7.5) −1.4 (−3.0 to 0.3) 0.11
Follow-up N = 36 16.8 (6.7) N = 35 18.5 (7.4)
Quadriceps twitch tension at rest (kg) Baseline N = 31 2.7 (1.1) N = 33 2.8 (1.6) 0.2 (0.0 to 0.4) 0.08
Follow-up N = 29 2.9 (1.3) N = 30 2.6 (1.2)
6-min walk distance (m) Baseline N = 40 336 (94) N = 40 330 (113) −9 (−29 to 12) 0.41
Follow-up N = 38 338 (104) N = 38 351 (111)
Postural change in systolic BPb (mmHg) Baseline N = 40 −11 (12) N = 40 −15 (16) −1 (−6 to 4) 0.79
Follow-up N = 38 −18 (11) N = 38 −18 (14)
Postural change in diastolic BPa (mmHg) Baseline N = 40 −3 (9) N = 40 −4 (6) −1 (−4 to 2) 0.48
Follow-up N = 38 −4 (9) N = 38 −4 (7)
Figures in brackets are SD unless otherwise noted.
aAdjusted for baseline values of variable under test.
bNegative values denote a fall in blood pressure on standing.
The effect of perindopril on postural instability in older people with a history of falls
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medications, including antihypertensives, on falls rates, but
withdrawal of antihypertensive medication in older people
with mild cognitive impairment and OH improved OH in
another recent trial [24].
Our previous trial of perindopril in older people showed
an improvement in 6MWD after 20 weeks of treatment
which we did not ﬁnd in this study [5]; however participants
in our previous trial were more functionally impaired, and
were selected because of functional impairment rather than
for their falls risk. It is therefore possible that in our previ-
ous trial, endurance rather than the fast-twitch muscle func-
tion that balance relies on was compromised, and that it
was endurance muscle function rather than fast-twitch
function that responded to ACEi.
Our trial had several strengths. The groups were well
balanced at baseline. We ensured that all participants had
had the opportunity to receive currently available interven-
tions for falls—any inﬂuence of treatment was therefore
additional. The dropout rate was low (4%) which may sug-
gest that the study population, was ﬁtter than some people
routinely seen in geriatric medical practice. Some weak-
nesses also deserve comment. Only 2% of those invited to
participate (n = 4,289) were recruited to the study. This
response rate is similar to a previous study in which we
recruited functionally impaired older people to a clinical
trial of ACEi and exercise [25] but much lower than that
seen in other trials using pharmacological approaches to
improve physical function (randomisation rates typically
5–10% of those approached) [5]. This demonstrates the dif-
ﬁculty in recruiting older people to trials of pharmaceutical
interventions, but also suggests speciﬁc issues around
recruitment to studies examining falls interventions. We did
not perform formal tests of cognitive function. The study
was of 15 weeks duration and may be too short to reach
deﬁnite conclusions, although our previous trial demon-
strated that differences in walk speed had started to appear
by 10 weeks. A larger number of participants in the peri-
ndopril group discontinued medication (7 versus 2)—
mostly due to cough (n = 4), a common side effect of
ACEi.
What do our results mean for clinical practice? The
results do not support a strategy of using ACEi to reduce
falls in older people with a history of falls, but they equally
suggest that ACEi may not have a deleterious effect on key
risks for falls, including OH. There may therefore be little
to gain by stopping ACEi in those who fall, particularly if
other indications for ACEi (e.g. heart failure, previous
stroke or other vascular event) are present. Further work,
including pooling of falls data from multiple trials of ACEi
in older people, would help to further clarify the effect of
ACEi on falls risk in this patient population.
Key points
• We conducted a trial of ACE inhibitors (ACEi) as a
pharmacological approach to improving postural sway.
• We found no improvement in postural sway to support a
role for ACEi in improving postural balance.
• We found no worsening of falls rates or OH to support
stopping ACEi in people with falls.
Supplementary data
Supplementary data are available at Age and Ageing online.
The full trial protocol and statistical analysis plan are avail-
able on request from the authors.
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